Bal Pharma Limited (BALPHARMA) AI Stock Analysis

• Market Cap: ₹1.20B
• Dividend Yield: 1.62%
• Average Volume (3M): 4.08K
• Price to Earnings (P/E): 16.4
• Beta (1Y): 0.48
• Revenue Growth: -9.07%
• EPS Growth: 5.36%
• Country: IN
• Employees: 868
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.12
• Shares Outstanding: 15,920,872
• 10 Day Avg. Volume: 4,315
• 30 Day Avg. Volume: 4,084
• PEG Ratio: -6.10
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 0.43
• P/FCF Ratio: -9.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ₹73.00 ▼(-1.23% Downside)
• Action: Reiterated Date: 11/01/25
• Date: Action: Reiterated 11/01/25

Bal Pharma Limited's overall stock score is primarily influenced by its financial performance and technical analysis. The company shows moderate growth but faces profitability and cash flow challenges. The technical indicators suggest a bearish trend, while the valuation appears fair. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Diversified product mix (Formulations & APIs)

A dual business model spanning finished dosage formulations and APIs provides durable revenue diversification. Selling both branded/generic medicines and bulk APIs to other manufacturers reduces single-market exposure, supports volume flexibility and helps stabilize revenues across cycles over the next 2–6 months.

Negative Factors

High leverage

Significant leverage increases interest and refinancing risk and reduces financial flexibility. Elevated debt burdens can constrain investment, raise vulnerability to input-price or demand shocks, and pressure liquidity if cash flows deteriorate, making capital structure a key medium-term risk.

Bal Pharma Limited Business Overview & Revenue Model

Company Description

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bu...

Read more

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bu...

How the Company Makes Money

Bal Pharma makes money primarily by selling pharmaceutical products across two main lines of business: (1) finished dosage formulations and (2) APIs (active pharmaceutical ingredients). Revenue from formulations is generated through the manufactur...

Read more

Bal Pharma makes money primarily by selling pharmaceutical products across two main lines of business: (1) finished dosage formulations and (2) APIs (active pharmaceutical ingredients). Revenue from formulations is generated through the manufactur...

Bal Pharma Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.95B	3.03B	3.39B	3.04B	2.81B	2.47B
Gross Profit	1.25B	730.18M	770.20M	1.25B	1.11B	993.03M
EBITDA	312.60M	317.63M	320.23M	245.00M	239.71M	257.82M
Net Income	71.58M	72.15M	73.92M	25.72M	56.12M	47.42M
Balance Sheet
Total Assets	0.00	3.36B	3.20B	3.13B	2.61B	2.40B
Cash, Cash Equivalents and Short-Term Investments	105.19M	105.19M	199.29M	74.63M	60.84M	39.71M
Total Debt	0.00	1.50B	1.42B	1.33B	1.07B	1.12B
Total Liabilities	-774.04M	2.58B	2.50B	2.49B	2.02B	1.87B
Stockholders Equity	774.04M	774.16M	692.94M	637.89M	586.27M	535.81M
Cash Flow
Free Cash Flow	11.28M	-145.55M	118.26M	-164.89M	192.39M	183.68M
Operating Cash Flow	88.16M	42.32M	228.06M	-18.43M	277.08M	217.81M
Investing Cash Flow	27.27M	-156.53M	-188.91M	-221.82M	-94.85M	-49.80M
Financing Cash Flow	-130.00M	90.12M	-12.06M	244.00M	-181.34M	-166.32M

Bal Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 73.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALPHARMA, the sentiment is Positive. The current price of 73.91 is above the 20-day moving average (MA) of 68.18, above the 50-day MA of 70.87, and below the 200-day MA of 81.25, indicating a neutral trend. The MACD of -0.62 indicates Negative momentum. The RSI at 61.04 is Neutral, neither overbought nor oversold. The STOCH value of 94.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BALPHARMA.

Bal Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALPHARMA	58 Neutral	₹1.20B	16.40	―	1.62%	-9.07%	5.36%
BAFNAPH	58 Neutral	₹3.14B	48.53	―	―	-0.77%	2055.99%
VAISHALI	52 Neutral	₹662.45M	21.33	―	―	18.35%	-154.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MANGALAM	50 Neutral	₹493.52M	-1.11	―	―	-24.55%	-310.57%
AAREYDRUGS	47 Neutral	₹1.86B	84.53	―	―	-17.47%	-50.07%
KREBSBIO	45 Neutral	₹1.26B	-11.90	―	―	-46.31%	-26.28%